<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZONISAMIDE <img border="0" src="../images/pr.gif"/></span><br/>(zon-i'sa-mide)<br/><span class="topboxtradename">Zonegran<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span>; <span class="classification">sulfonamide</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Anticonvulsant effective against a variety of seizure types. A sulfonamide derivative and a broad spectrum anticonvulsant
         that does not potentiate the activity of gamma-aminobutyric acid (GABA) in the synapses of the neurons. It does, however,
         facilitate dopaminergic and serotonergic neurotransmission.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses focal spike discharges and electroshock seizures.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial seizures in adults.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Bipolar disorder.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sulfonamides or zonisamide; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Partial Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 100 mg q.d., may increase after 2 wk to 200 mg/d, may then increase q2wk, if necessary (max: 400 mg/d in 12
               divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not crush or break capsules; ensure capsules are swallowed whole with adequate fluid.</li>
<li>Withdraw drug gradually when discontinued to minimize seizure potential.</li>
<li>Store at 25° C (77° F); room temperature permitted. Protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flu-like syndrome, weight loss. <span class="typehead">CNS:</span> Agitation, irritability, anxiety, ataxia, confusion, depression, difficulty concentrating, difficulty with memory, <span class="speceff-common">dizziness,</span> fatigue, <span class="speceff-common">headache,</span> insomnia, mental slowing, nervousness, nystagmus, paresthesia, schizophrenic behavior, <span class="speceff-common">somnolence,</span> tiredness, tremor, convulsion, abnormal gait, hyperesthesia, incoordination. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">anorexia,</span> constipation, diarrhea, dyspepsia, nausea, dry mouth, flatulence, gingivitis, gum hyperplasia, gastritis, stomatitis, cholelithiasis,
      glossitis, melena, rectal hemorrhage, ulcerative stomatitis, ulcer, dysphagia. <span class="typehead">Metabolic:</span> Oligohidrosis, sometimes resulting in heat stroke and hyperthermia in children. <span class="typehead">Respiratory:</span> Rhinitis, pharyngitis, cough. <span class="typehead">Skin:</span> Ecchymosis, rash, pruritus. <span class="typehead">Special Senses:</span> Difficulties in verbal expression, diplopia, speech abnormalities, taste perversion, amblyopia, tinnitus. <span class="typehead">Urogenital:</span> Kidney stones. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Phenytoin,</b>
<b>carbamazepine,</b>
<b>phenobarbital,</b>
<b>valproic acid</b> may decrease half-life of zonisamide. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 26 h. <span class="typehead">Distribution:</span> 40% protein bound, extensively binds to erythrocytes. <span class="typehead">Metabolism:</span> Acetylated in liver by CYP3A4. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 63105 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician if an unexplained rash or S&amp;S of hypersensitivity appear (see Appendix F).</li>
<li>Monitor for and report S&amp;S of CNS impairment (somnolence, excessive fatigue, cognitive deficits, speech or language problems,
            incoordination, gait disturbances); oligohidrosis (lack of sweating) and hyperthermia in pediatric patients.
         </li>
<li>Lab tests: Periodic BUN and serum creatinine, and CBC with differential.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not abruptly stop taking this medication.</li>
<li>Increase daily fluid intake to minimize risk of renal stones. Notify physician immediately of S&amp;S of renal stones: sudden
            back or abdominal pain, and blood in urine.
         </li>
<li>Report any of the following: dizziness, excess drowsiness, frequent headaches, malaise, double vision, lack of coordination,
            persistent nausea, sore throat, fever, mouth ulcers, or easy bruising.
         </li>
<li>Exercise special caution with concurrent use of alcohol or CNS depressants.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>